NEW YORK (GenomeWeb News) – Pacific Biosciences has filed a prospectus for the resale of up to 5.5 million shares of its stock, issuable upon the exercise of warrants.

The Palo Alto, Calif.-based company is not selling any securities under the prospectus, and while it will receive no proceeds from the sale of shares issuable upon exercise of the warrants, it could receive gross proceeds of about $14.5 million if all of the warrants are exercised for cash, PacBio said in its document filed with the US Securities and Exchange Commission on Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.